John Doux
Director/Board Member at Lutris Pharma Ltd.
Profile
John Doux is currently a Director at Palvella Therapeutics, Inc. and Lutris Pharma Ltd.
He previously worked as an Analyst at Palo Alto Investors LP.
Before that, he was a Director at Brickell Subsidiary, Inc. and ACELYRIN, Inc. Dr. Doux received his undergraduate and doctorate degrees from Stanford University and his MBA from The Wharton School of the University of Pennsylvania.
John Doux active positions
Companies | Position | Start |
---|---|---|
Palo Alto Investors LP
Palo Alto Investors LP Investment ManagersFinance Palo Alto Investors LLC (PAI) is a registered investment advisor and hedge fund manager headquartered in Palo Alto, California. The firm was founded by William L. Edwards in 1989 as Palo Alto Investors LLC and converted into a California limited partnership in 2018. They are a subsidiary of PAI LLC. PAI serves as the investment adviser to private pooled investment vehicles, the securities of which are offered to investors on a private placement basis. | Analyst-Equity | 31/12/2003 |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Director/Board Member | - |
Lutris Pharma Ltd.
Lutris Pharma Ltd. Pharmaceuticals: MajorHealth Technology Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel. | Director/Board Member | - |
Former positions of John Doux
Companies | Position | End |
---|---|---|
ACELYRIN, INC. | Director/Board Member | - |
Brickell Subsidiary, Inc.
Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Director/Board Member | - |
Training of John Doux
Stanford University | Doctorate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ACELYRIN, INC. | Health Technology |
Private companies | 4 |
---|---|
Palo Alto Investors LP
Palo Alto Investors LP Investment ManagersFinance Palo Alto Investors LLC (PAI) is a registered investment advisor and hedge fund manager headquartered in Palo Alto, California. The firm was founded by William L. Edwards in 1989 as Palo Alto Investors LLC and converted into a California limited partnership in 2018. They are a subsidiary of PAI LLC. PAI serves as the investment adviser to private pooled investment vehicles, the securities of which are offered to investors on a private placement basis. | Finance |
Brickell Subsidiary, Inc.
Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Health Technology |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Health Technology |
Lutris Pharma Ltd.
Lutris Pharma Ltd. Pharmaceuticals: MajorHealth Technology Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Stock Market
- Insiders
- John Doux